NASDAQ$MNKD
MannKind Corp · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
MannKind reported first quarter 2022 financial results.
MannKind Corporation reported total revenues of $12.0 million for the first quarter of 2022, with Afrezza net revenue increasing by 21% compared to the first quarter of 2021. The net loss for the quarter was $26.0 million, or $0.10 per share.
- Afrezza Net Revenue of $9.8 million, a 21% increase compared to Q1 2021.
- Afrezza Gross Margin was 77%, with Gross Profit increasing by 99% compared to Q1 2021.
- Cash, Cash Equivalents, and Investments totaled $233.0 million as of March 31, 2022.
- Tyvaso DPI PDUFA date is set for May 2022.
Headline financials
Revenue & EPS history
MannKind · Revenue · Quarterly
$12M
Revenue by segment
MannKind · $31M total across 3 segments · Q3 2023
- Afrezza$13.5M—43.4%
- Collaborations and services$13.1M—42.2%
- V-Go$4.45M—14.3%
Forward guidance
The company is focused on supporting United Therapeutics in their planned commercial launch of Tyvaso DPI.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
-0.4%
Avg return
Earnings day
-0.7%
Avg return
5 days after
+1.5%
Avg return
30 days after
39%
25 / 64 earnings
Positive
+44.9%
Q3 2016
Best reaction
-28.5%
Q1 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +24.5% | +17.5% | +18.5% | |
| Q4 2025 | -6.9% | -16.3% | -34.9% | |
| Q3 2025 | +10.6% | -1.1% | +3.6% | |
| Q1 2025 | -4.5% | -2.7% | -9.7% | |
| Q4 2024 | -4.4% | -5.9% | -8.0% | |
| Q3 2024 | -1.2% | -4.8% | -8.6% | |
| Q2 2024 | -1.5% | -1.5% | +12.5% | |
| Q1 2024 | -3.6% | -1.3% | +4.5% | |
| Q4 2023 | +9.5% | +25.7% | +26.5% | |
| Q3 2023 | -0.8% | -6.8% | -0.3% | |
| Q2 2023 | +15.5% | +11.2% | -3.8% | |
| Q1 2023 | +13.4% | +9.0% | +6.2% | |
| Q4 2022 | +4.2% | +1.7% | -23.1% | |
| Q3 2022 | +6.3% | +20.7% | +32.8% | |
| Q2 2022 | -1.4% | -4.6% | -9.0% | |
| Q1 2022 | -8.7% | -8.7% | +42.7% | |
| Q4 2021 | -25.7% | -24.9% | -5.2% | |
| Q3 2021 | -0.6% | +3.1% | -14.3% | |
| Q2 2021 | +5.1% | +5.4% | +20.8% | |
| Q1 2021 | -8.4% | -3.9% | -8.0% | |
| Q4 2020 | -4.5% | -36.8% | -40.0% | |
| Q3 2020 | +8.8% | +19.0% | +43.9% | |
| Q2 2020 | +0.0% | -4.2% | -1.2% | |
| Q1 2020 | -2.2% | -0.7% | +4.5% | |
| Q4 2019 | -7.9% | -16.4% | -27.6% | |
| Q3 2019 | -15.1% | -16.8% | -18.8% | |
| Q2 2019 | -0.9% | +4.6% | +13.9% | |
| Q1 2019 | -12.3% | -19.4% | -25.2% | |
| Q4 2018 | +23.8% | +17.2% | +27.8% | |
| Q3 2018 | +0.0% | -1.1% | -2.7% | |
| Q2 2018 | -26.8% | -29.3% | -29.9% | |
| Q1 2018 | +2.3% | +8.7% | +13.3% | |
| Q4 2017 | -10.4% | -13.5% | -30.3% | |
| Q3 2017 | -7.1% | +0.3% | -4.3% | |
| Q2 2017 | -5.7% | -2.5% | +61.5% | |
| Q1 2017 | +13.8% | -5.4% | +39.3% | |
| Q4 2016 | +9.9% | +2.5% | -34.2% | |
| Q3 2016 | +44.9% | +51.2% | +51.2% | |
| Q2 2016 | -6.2% | +2.0% | -27.6% | |
| Q1 2016 | -28.5% | — | — | |
| Q4 2015 | +6.0% | — | — | |
| Q3 2015 | -19.9% | — | — | |
| Q2 2015 | +4.5% | — | — | |
| Q1 2015 | -8.4% | — | — | |
| Q4 2014 | +2.8% | — | — | |
| Q3 2014 | -1.5% | — | — | |
| Q2 2014 | -8.0% | — | — | |
| Q1 2014 | +5.8% | — | — | |
| Q4 2013 | +5.9% | — | — | |
| Q3 2013 | +7.3% | — | — | |
| Q2 2013 | -5.1% | — | — | |
| Q1 2013 | +11.0% | — | — | |
| Q4 2012 | -1.9% | — | — | |
| Q3 2012 | +2.6% | — | — | |
| Q2 2012 | +3.9% | — | — | |
| Q1 2012 | -8.3% | — | — | |
| Q4 2011 | +7.9% | — | — | |
| Q3 2011 | -1.6% | — | — | |
| Q2 2011 | -10.1% | — | — | |
| Q1 2011 | -11.8% | — | — | |
| Q4 2010 | -5.5% | — | — | |
| Q3 2010 | -2.3% | — | — | |
| Q2 2010 | -0.7% | — | — | |
| Q1 2010 | +3.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro